Limits...
Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO-07 study.

Chibaudel B, Lacave R, Lefevre M, Soussan P, Antoine M, Périé S, Belloc JB, Banal A, Albert S, Chabolle F, Céruse P, Baril P, Gatineau M, Housset M, Moukoko R, Benetkiewicz M, de Gramont A, Bonnetain F, Lacau St Guily J - Cancer Med (2015)

Bottom Line: Secondary endpoints were crCR rates, overall response, pathological CR, progression-free survival, overall survival, and safety.Twelve (29%) patients required dose reduction.ETPF was associated with a tumor objective response rate (ORR) of 58%.

View Article: PubMed Central - PubMed

Affiliation: Division of Medical Oncology, Franco-British Hospital Institute, Levallois-Perret, France.

No MeSH data available.


Related in: MedlinePlus

CONSORT diagram.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4430265&req=5

fig01: CONSORT diagram.

Mentions: Forty-one patients (mITT population) started induction therapy (Fig.1). One patient did not receive an intended treatment due to investigator decision to replace cisplatin by carboplatin and not to administer cetuximab. Thirty-one (76%) patients and 36 (88%) patients received all nine planned doses of cetuximab and full three doses of planned chemotherapy, respectively. Dose reduction of cetuximab was required in two (5%) patients and in 10 (24%) patients for chemotherapy. Treatment had to be stopped early in eight (19%) patients, mainly due to limiting toxicity in five patients (diarrhea, febrile neutropenia, neutropenia without fever, diarrhea with febrile neutropenia, and skin toxicity), one toxic death (colonic perforation), one acute pancreatitis, and one consent withdrawal.


Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO-07 study.

Chibaudel B, Lacave R, Lefevre M, Soussan P, Antoine M, Périé S, Belloc JB, Banal A, Albert S, Chabolle F, Céruse P, Baril P, Gatineau M, Housset M, Moukoko R, Benetkiewicz M, de Gramont A, Bonnetain F, Lacau St Guily J - Cancer Med (2015)

CONSORT diagram.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4430265&req=5

fig01: CONSORT diagram.
Mentions: Forty-one patients (mITT population) started induction therapy (Fig.1). One patient did not receive an intended treatment due to investigator decision to replace cisplatin by carboplatin and not to administer cetuximab. Thirty-one (76%) patients and 36 (88%) patients received all nine planned doses of cetuximab and full three doses of planned chemotherapy, respectively. Dose reduction of cetuximab was required in two (5%) patients and in 10 (24%) patients for chemotherapy. Treatment had to be stopped early in eight (19%) patients, mainly due to limiting toxicity in five patients (diarrhea, febrile neutropenia, neutropenia without fever, diarrhea with febrile neutropenia, and skin toxicity), one toxic death (colonic perforation), one acute pancreatitis, and one consent withdrawal.

Bottom Line: Secondary endpoints were crCR rates, overall response, pathological CR, progression-free survival, overall survival, and safety.Twelve (29%) patients required dose reduction.ETPF was associated with a tumor objective response rate (ORR) of 58%.

View Article: PubMed Central - PubMed

Affiliation: Division of Medical Oncology, Franco-British Hospital Institute, Levallois-Perret, France.

No MeSH data available.


Related in: MedlinePlus